DUBLIN–(BUSINESS WIRE)–The “Market
Spotlight: Opioid-Induced Constipation” report has been added
to ResearchAndMarkets.com’s offering.
This Market Spotlight report covers the Opioid-Induced Constipation
market, comprising key marketed and pipeline drugs, clinical trials,
upcoming and regulatory events, patent information, probability of
success, epidemiology data, and licensing and acquisition deals, as well
as presenting drug-specific revenue forecasts
Key Takeaways
-
The approved drugs in the opioid-induced constipation (OIC) space
predominantly target opioid receptors, with the exception of Amitiza,
a type-2 chloride channel activator. All of the marketed drugs are
administered via the oral route, with one product also being available
in a subcutaneous formulation. -
The majority of industry-sponsored drugs in active clinical
development for OIC are in Phase II, with only one drug in Phase III.
Therapies in mid-to-late-stage development for OIC target opioid
receptors and guanylyl cyclase c receptor. These therapies are
administered via the oral route. -
The overall likelihood of approval of a Phase I gastroenterology (non
inflammatory bowel disease)-other asset is 22.5%, and the average
probability a drug advances from Phase III is 66.7%. Drugs, on
average, take 10.1 years from Phase I to approval, compared to 9.9
years in the overall gastroenterology (non inflammatory bowel disease)
space. -
The clinical trials distribution across Phase I-IV indicates that the
majority of trials for OIC have been in the late phases of
development, with 61% in Phase III-IV, and only 39% in Phase I-II. -
Clinical trial activity in the OIC space is dominated by completed
trials. Shionogi has the highest number of completed trials for OIC,
with nine trials. -
Shionogi leads the industry sponsors with the highest number of
clinical trials for OIC, followed by Pfizer
Key Topics Covered:
OVERVIEW
KEY TAKEAWAYS
DISEASE BACKGROUND
TREATMENT
Management of OIC with laxatives
Management of OIC with opioid antagonists
Management of OIC with Amitiza, a secretagogue chloride channel activator
EPIDEMIOLOGY
Recent prevalence studies
Challenges
MARKETED DRUGS
PIPELINE DRUGS
KEY REGULATORY EVENTS
Two Orphans And An Avastin Biosimilar Among EU Approval Recommendations
CHMP Delays Review of Portola’s Ondexxya; Who Will Pass Muster?
PROBABILITY OF SUCCESS
PARENT PATENTS
REVENUE OPPORTUNITY
CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase
BIBLIOGRAPHY
Prescription information
For more information about this report visit https://www.researchandmarkets.com/r/enlsp3
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Gastroenterology